We investigated the effects of A. galanga extract on metabolism and gene expression involved in the interleukin-1β (IL-1β) response of human chondrocyte and synovial fibroblast. A. galanga extract inhibited IL-1β enhanced matrix breakdown of the cartilage explants in a dose-dependent manner. It suppressed uronic acid loss from the tissue and decreased the release of sulfated GAG and hyaluronan into the medium. MMP-2 and MMP-9 activity in the culture medium of chondrosarcomas and synovial fibroblasts were significantly reduced in the presence of A. galanga extract, which also suppressed the production of MMP-1, -3 and -13. The A. galanga extract also significantly increased type II collagen, SOX9 and aggrecan gene expression, suggesting an ability to enhance anabolic activity. At a high dose of A. galanga extract there was a down-regulation of aggrecan gene expression. Comparison with Diacerein r showed its general anti-inflammatory potential to be similar. The A. galanga extract was shown to inhibit IL-1β-stimulated cartilage matrix degradation in both systems. Additionally, the extract showed the potential to up-regulate certain chondrocyte anabolic genes. It may, therefore, offer some cartilage protective and anti-inflammatory properties as a therapeutic agent in arthritis.
Introduction
Osteoarthritis (OA) is a degenerative process of the joints, which is characterized by the progressive destruction and erosion of cartilage often associated with an osteophytic response. This destruction results from a homeostatic imbalance between the matrix synthesis and degradation in the cartilage. Pro-inflammatory cytokines, such as interleukin-1β (IL-1β) and other mediators produced by cytokine action on chondrocyte and synovial fibroblasts may contribute to the process and cause an imbalance in extracelluar matrix (ECM) turnover, accelerate the degradation of cartilage matrix, and also increase the incidence of chondrocyte apoptosis [1, 2] . IL-1β (and TNFα) have been shown to provide a driving force for inducing and sustaining cartilage damage in arthritis by suppressing the synthesis of specific ECM molecules and by promoting excessive cartilage destruction, thereby preventing the cartilage repair process [3, 4] . Numerous studies have demonstrated that matrix metalloproteinases (MMPs) are key enzymes involved in the destruction of articular cartilage in arthritic diseases [5] . MMP-1/collagenase 1, MMP-3/stromelysin 1, MMP-9/gelatinase B and MMP-13/ collagenase 3 have been detected in synovium, synovial fluid, and cartilage samples in both RA and OA and have been directly implicated in the pathologic loss of articular cartilage [6] [7] [8] [9] [10] . Furthermore, pro-inflammatory cytokines, produced locally in the joint by monocytes/macrophages, synovial fibroblasts, or chondrocytes [11] , induce and/or augment the production of proMMPs [12] [13] [14] . This compromises the function of the chondrocytes, the highly differentiated cells of cartilage, which are responsible for maintaining a homeostatic balance between biosynthesis and degradation of cartilage ECM [15, 16] . The metabolic status of the chondrocyte thus plays a central role in our understanding of the initiation and progression of joint degeneration such as in OA [17] . In experimental OA models it has been shown that there is an initial anabolic response of chondrocyte with up-regulation of mRNA levels for the major structural components type II collagen and aggrecan and increases in the synthesis of the corresponding protein [18, 19] . The Sox9 transcription factor SOX9 (SRY-type HMG box proteins) has emerged as an important determinant of chondrocyte differentiation, including the regulation of type II collagen (Col2) and aggrecan gene expression [20, 21] . Degradation of the ECM is also elevated in these early stages in OA and, as the disease progresses, the chondrocyte anabolic response becomes insufficient. This results in depletion of the ECM, which occurs during the later stages of OA. Loss of key matrix organization results in a compromised tissue function and, eventually, cartilage loss down to the sub-chondral bone.
The Thai herb, Alpinia galanga (B.L. Burtt) has been used in traditional medicine for its carminative, stomachic, anti-rheumatic, anti-flatulent, and anti-itching therapeutic qualities. It also contains anti-microbial agents [22, 23] . The rhizomes of this plant are extensively used as a spice in Southeast Asian countries. The potential anti-inflammatory actions are attributed to suppressing prostaglandin synthesis through the inhibition of cyclooxygenase-1 and cyclooxygenase-2 [24] . In addition, the aqueous acetone extract from the rhizomes has been reported to have inhibitory effects on lipopolysaccharide (LPS)-induced nitric oxide (NO) production [25] . In order to evaluate the potential of A. galanga extract for chondroprotective effects in arthritis, we investigated its effect on IL-1β induced cartilage degradation and on catabolic and anabolic processes in a human chondrosarcoma, cell-lined SW1353 and in human synovial fibroblasts.
Experimental procedures

Preparation of Alpinia galanga hexane extract
The Galanga powder (from fresh rhizomes of A. galanga L.) was obtained from The Communo Life of Love and Unity of the Mountain People Foundation (CLUMP). Dried powder of A. galanga was extracted with hexane and, to ensure complete extraction, 5 kg powder was extracted with 17 L of hexane. This process was repeated 4 times. The filtrates from the extractions were mixed and dried in a rotary evaporator under reduced pressure at 40
• C. The yield was determined and the dried residue was weighed and stored at -20 • C.
Explants preparation and treatment
Porcine articular cartilage, freshly dissected from a metacarpophalangeal joint of a 20-24 week old animal was incubated in serum-free-DMEM containing 200 units/ml penicillin and 200 μg/ml streptomycin. The explants were maintained in culture in a humidified incubator with 5% CO 2 at 37
Explants at day 2 were maintained in media without serum for 24 hours (day 0 media) prior to the three days of treatment. Conditioned media were collected on day 3 of culture and stored at -20
• C until analyzed. Recombinant human interleukin-1β (25 ng/ml) was added to induce cartilage degradation and the effects of the A. galanga extract was tested at concentrations ranging from 6.25 -10 μg/ml. As an independent control Diacerein r , (0.0625 -1 μM) a commercial anti-osteoarthritis drug (TRB Chemedica, Switzerland), was added to parallel cultures as a standard agent. Each experiment contained a control in which no IL-1β was added to the medium. Treatments were performed in triplicate using tissue from one animal donor. • C and 3 h digestion with collagenase (Sigma type IA) at 37
The cells were washed with PBS and grown in DMEM containing 10% FCS as high density primary monolayer cultures until confluency. The synovial fibroblasts at passage 4 were maintained in serum-free medium and treated as described for SW1353 cells.
Cytotoxicity detection
Quantification of cell death and cell lysis was determined by a colorimetric assay, based on the measurement of lactate dehydrogenase (LDH) activity in culture medium [26] . The analysis was conducted according to the manufacturer's instruction by comparing the amount of LDH in the samples with the positive control: cells treated with 0.5 mM H 2 O 2 for 24 h.
Measurement of glycosaminoglycan levels
The level of glycosaminoglycan appearing in the medium of explants, cell cultures, and papain-digested cells was determined using the dimethylmethylene blue (DMMB) assay for sulfated glycosaminoglycan [27] , using chondroitin sulfate C (shark cartilage extract; Sigma-Aldrich, USA) as standard. The DMMB solution was added to the diluted sample and standards and appropriate blank solution prior to absorbance reading at 525 nm in a microplate reader spectrophotometer. The release of sGAG was estimated by the calculation:
% sGAG release = [sGAG in medium/(sGAG in medium + sGAG in cell layer)] × 100
Determination of uronic acid
Glucuronic acid (GlcUA) concentrations in the papain digested explants were determined with the colorimetric assay using m-hydroxydiphenyl [28] with D-glucuronic acid lactone as the standard.
Measurement of hyaluronan levels
HA in medium and cell layer was measured using a competitive inhibition-based-ELISA as previously described, with modifications [29] . Briefly, culture media or papain-digested samples containing unknown amounts of HA (175 μl 
Gene expression analysis
RNA was extracted from monolayer cells using an Aurum total RNA purification kit (Bio-Rad Laboratories, Hercules, CA, USA) according to the manufacture's guidelines. Total RNA (500ng) of each sample was reverse transcribed into complementary DNA (cDNA) using RevertAid T M First Strand cDNA synthesis kit (MBI Fermentas, Germany). Primers and probe sets were designed using Primer Express 2.0 software (Applied Biosystems, Foster City, CA, USA) to meet Taqman r requirements and were designed to bind to separate exons to avoid false positive results arising from amplification of contaminating genomic DNA. The primer nucleotide sequences are shown in Table 1 . The amplified products were electrophoresed on 2% (w/v) agarose gels, stained with ethidium bromide, and then imaged using a Bio-Rad Gel-Doc fluorescent image analyzer. The integrated densities were then calculated using Scion image analysis software and normalized to the house-keeping gene GAPDH (glyceraldehydes-3-phosphate dehydrogenase) to permit semi-quantitative comparisons in mRNA levels as previously described [30, 31] . 
Gelatin zymography
Pro-MMP-2 and MMP-9 in the conditioned medium were detected by gelatin zymography as previously described [32] . The samples were subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) using a 10% acrylamide gel containing 0.1 mg/ml of gelatin (Sigma-Aldrich, USA) under non-reducing conditions at 4 • C. After electrophoresis, SDS in the gel was removed by rinsing with 2.5% Triton-X 100 pH 7.5. The gel was then incubated at 37
• C in the incubating buffer (50 mM Tris-HCl, 5 mM CaCl 2 , 1 μM ZnCl 2 , 0.02% NaN 3 ) for 18 h. After incubation, the gel was stained with 0.1% Coomassie brilliant blue R250 (Bio-Rad Laboratories, Hercules, CA) in 50% methanol /10% acetic acid, and destained with 10% acetic acid /50% methanol. The gelatinolytic activity was analyzed using Scion image software (Scion Corporation, USA).
Results
A. galanga extract inhibited IL-1β-induced degradation of extracellular matrix in porcine cartilage explants
To investigate the effects of A. galanga extract on extracellular matrix degradation, porcine cartilage explants were incubated with pro-inflammatory cytokine, IL-1β (at 25 ng/ml) with a range of doses of A. galanga extract. After 3 days of treatments the cartilage tissue was analyzed for uronic content and the culture media were analyzed for s-GAG and HA release. The results showed that the IL-1β caused a 20% decrease in the uronic acid content of the cartilage over 3 days (data not shown) and the release of extracellular matrix (ECM) components, s-GAG and HA into the culture medium was increased 50% and 60%, respectively (Fig. 1A) . The A. galanga extract at 25-100 μg/ml dose-dependently inhibited the loss of uronic acid from cartilage (data not shown) and decreased the release of s-GAG and HA to the medium (Fig. 1A) . The effect of the A. galanga extract was found to be comparable to the inhibitory effects detected in the same test system with the positive control, Diacerein r (0.0625-1 μM) (Fig. 1B) . 3.2 Effect of A. galanga extract on the s-GAG production/release in SW1353 cells and in human synovial fibroblasts
Having obtained evidence that A. galanga extract was able to inhibit cartilage degradation driven by IL-1β using the cartilage explant culture model, additional experiments were carried out with a human chondrocyte-like cell line SW1353, and with cultured primary human synovial fibroblasts to explore further its mode of action. The cells were investigated at confluency when they had accumulated some pericellular matrix from this cell layer. It was found that the untreated SW1353 cells and synovial fibroblasts released 2.8 + 0.5% and 5.0 + 0.6% of s-GAG, respectively into the culture medium ( Fig. 2A, 3A) . When the samples were treated with IL-1β (10 ng/ml), a significant increase was observed in the basal s-GAG release up to 10.8 + 0.2% (SW1353) and 14.0 + 0.4% (synovial fibroblasts). The A. galanga extract treatment of SW 1353 increased the sGAG release relative to total sGAG (% sGAG release). With the synovial fibroblasts the A. galanga extract inhibited the small IL-1β increase and further suppressed release below the control untreated value. Diacerein r in these cell systems showed no inhibition of IL-1β stimulated release and at high dose (∼2.5-5 μM) it appeared to enhance the production of s-GAG in both SW1353 cells and synovial fibroblasts (Fig. 2B, 3B ) causing even greater release into the culture medium.
Effect of A. galanga extract on the Hyaluronan production/release in SW1353 cells and in human synovial fibroblasts
In the same cell systems there was also significant release of hyaluronan (HA) into the culture medium and SW1353 cells with IL-1β showed a significant increase (∼50%). The A. galanga extract was shown to inhibit this IL-1β-stimulated release of HA ( Fig. 2A) . With synovial fibroblasts the control release of HA was small but significant and IL-1β (10 ng/ml) slightly stimulated the HA release (Fig 3A) . Diacerein r at the high dose (∼2.5-5 μM) was also effective in inhibiting the HA release from SW1353 and synovial fibroblast cultures (Fig. 2B, 3B ).
Effect of A. galanga extract on the IL-1β-induced pro-MMP-2 production and expression of MMP-1, -3 and -13 mRNA
As metalloproteinases have an important role in the regulation of extracellular matrix turnover and are typically highly expressed in tissues in joint disease we investigated the expression of some selected metalloproteinases to understand if A. galanga extract may have activity in suppressing their expression. To assess the gelatinases (MMP-2 and MMP-9), gelatin zymography experiments have been performed and it was indicated that chondrosarcomas (SW1353 cells) and synovial fibroblasts in culture produced small amounts of pro-MMP2 and pro-MMP-9 (Fig 4) . When confluent SW1353 cells and synovial fibroblasts were treated with IL-1β (10ng/ml) for 24 h, the level of proMMP-2 and -9 in the conditioned medium of SW1353 and human synovial fibroblasts showed a small increase (about 1.6 and 1.8 fold, respectively), compared with the untreated control cells (Fig. 4) . The A. galanga extract (1-50 μg/ml) suppressed the IL-1β-induced pro-MMP-2 production in a dose-dependent manner with a maximal inhibition at 50 μg/ml of 73.5% and 68.7%, in SW1353 cells and synovial fibroblasts, respectively. Diacerein r (0.001-2.5 μM) also effectively suppressed the production of proMMP-2 and -9.
To assess other important metalloproteinases, we investigated the expression of MMP-1,-3 and -13 genes by semi-quantitative RT-PCR. The expression of MMP-1,-3,and -13 were strongly increased in confluent SW1353 cells treated with IL-1β (10 ng/ml) for 24 h (Fig. 5) . The effects of A. galanga extract showed strong inhibition (74%) of MMP-1 expression, but only a small inhibition of MMP-3 (17%) and MMP-13 (12%). Diacerein r only showed inhibition of their expression (44.4, 37.3 and 53.6% reduction, respectively) at the highest dose (2.5 μM) (Fig. 6) . The synovial fibroblast cultures also showed increased expression of the MMP when treated with IL-1β (Fig. 7) . The A. galanga extract was more effective at reducing their expression in the synovial fibroblasts than in the SW1353 cells and at high dose (10 μg/ml) it reduced the MMPs expression by 77%, 62% and 65% for MMP-1, -3 and -13, respectively (Fig. 7) . Diacerein r also downregulated the expression of MMP-1, -3, and -13 mRNAs (Fig. 8 ) in a dose-dependent manner (0.1 − 2.5 μM) and gave maximum reduction at 2.5 μM (81%, 89% and 75%, respectively).
Fig. 4 Effect of (A)
A. galanga extract, (B) Diacerein r on the production of gelatinases, MMP-2, and MMP-9. Confluent SW1353 cells or synovial fibroblasts were treated with IL-1β (10 ng/ml) in the presence and absence of A. galanga extract or Diacerein r for 24 h. and then the conditioned culture medium was analyzed by gelatin zymography as described in methods.
Three independent experiments using cells of different origin gave reproducible results and typical data are shown. M, protein marker; C, control. The numbers denoted the quantify density value based on Scion image software.
3.5 Effect of A. galanga extract on the IL-1β effects on the expression of aggrecan, collagen type II, and SOX9 expression
Since the maintenance of cartilage matrix is a balance between biosynthesis and degradation an important factor in addition to degradation is the continued biosynthetic activity of the cells. The effects of the A. galanga extract were thus assessed on the gene expression in the SW1353 cells of the cartilage macromolecules such as aggrecan, collagen and the key chondrocyte transcription factor SOX9. In response to 10 ng/ml of IL-1β, collagen type II and SOX9 expression at 24 h decreased by (12% and 56%, respectively) compared to the untreated control culture, (Fig. 5) . In the presence of the A. galanga extract collagen type II gene expression with IL-1β was further increased. For SOX9 Fig. 5 Effect of A. galanga extract on the mRNA expression of cartilage genes (AGG, COL2 and SOX9) and proteinases (MMP-1, -3, -13). Confluent SW1353 cells were cultured with IL-1β (10 ng/ml) in the presence and absence of the A. galanga extract for 24 h. * Denoted value that was significantly different (p < 0.05) from the IL-1β treated control. Confluent human synovial fibroblasts were cultured with IL-1β (10 ng/ml) in the presence and absence of the Diacerein r for 24 h.
* Denoted value that was significant different (p < 0.05) from the IL-1β treated control.
the A. galanga extract reversed the IL-1β inhibition in dose-dependent way (1 ng/ml -10 ug/ml) and at high dose it exceeded the non-IL-1β control level (Fig. 5) . Aggrecan gene expression slightly increased (11%) with IL-1β treatment compared to the untreated control. A. galanga extract at a low dose (1ng/ml -0.1 μg/ml) enhanced aggrecan gene expression but, in contrast, at a high dose (0.1-10 μg/ml), there was inhibition of gene expression to down to a level below that which was observed as the control value. Diacerein r (0.01 -2.5 μM) also showed some stimulation at higher doses for aggrecan and SOX9 gene expression in the presence of IL-1β, whereas there was only a slight effect on collagen type II gene expression (Fig. 6 ).
Discussion
Arthritis is a major debilitating disease and affects millions of people all over the world. Part of the process that leads to pain and disability is the degeneration and eventual loss of articular cartilage. This involves a range of growth factor and cytokine responses that lead to matrix degradation driven by matrix proteinases such as MMPs and aggrecanases.
The inflammatory cytokine IL-1β is involved in a variety of pathological processes, such as the response to infection, activated lymphocyte products, microbial toxins, and other stimuli [33] . It has particularly damaging effects on articular cartilage as it induces matrix MMPs and inhibits ECM synthesis by chondrocytes and suppresses chondrocyte proliferation [34] . Diacerein r (4,5-diacetoxy-9,10-dioxo-9,10-dihydroanthracene-2-carboxylic acid) has been used in the long-term treatment of OA [35] [36] [37] and it is currently under evaluation as a disease-modifying OA drug in randomized placebo-controlled clinical trails of patients with OA of the hip and knee. The efficacy of Diacerein r has been well documented in animal models including the post-contusive rabbit model and the accelerated canine model of OA [38, 39] . It has been shown to inhibit pro-inflammatory cytokine synthesis and activity, particularly for IL-1β [39] and in vitro experiments showed it was able to inhibit IL-1β induced collagen synthesis [40] . In OA animal models, this drug has shown to suppress cartilage matrix degradation. In the present study the results showed that Diacerein r could significantly inhibit the release of cartilage matrix proteoglycans and pro-MMP-2 and -9, when cartilage explants were stimulated with IL-1β. Moreover, it was also shown to down-regulate the expression of the MMP-1, -3 and, -13 genes, which is in complete agreement with the previous study [41] . The present study was carried out to evaluate the effect of the hexane extract of the rhizomes of A. galanga on some activities relevant to joint degeneration. The initial experiments established that the A. galanga extract was able to inhibit proteoglycan and HA loss from articular cartilage explants stimulated with IL-1β for 3 days. It thus contained an activity of potential benefit in reducing matrix degradation. Furthermore in subsequent work it showed no cytotoxic effects on cells, which might otherwise contribute to the inhibition of matrix damage. In order to assess further the possible mode of action of the A. galanga extract its activity was investigated in two cell systems (SW1353 cells and synovial fibroblasts) looking at proteoglycan and HA release from cell layer and on gelatinase activity and other MMP and chondrocyte gene expression. The proteoglycan and HA release is likely to be a combined effect of degradative release from the cell layer and changes in rates of synthesis and secretion from the cell into the cell layer and into the medium. The effects of the A. galanga extract thus appear to be either by inhibiting IL-1β stimulated cell layer release or by inhibiting IL-1β stimulated increase in synthesis. Both chondrosarcomas and synovial fibroblasts are relevant models for assessing ECM molecule release as a synthetic process. However, this process might be via multiple mechanisms and must be tested in the future. As it also appeared to have (1) some inhibitory actions in SW1353 cells on pro-gelatinase expression (MMP-2, MMP-9), (2) some inhibitory effect on MMP-1 and MMP-3 and, (3) some small effect on MMP-13, it appears that at least some of its action in suppressing cytokine-stimulated matrix degradation may be to decrease extracellular proteinase activity. Inhibition of mRNA for the matrix-degrading enzymes, MMP-1, -3 and -13, in synovial fibroblasts suggests that A. galanga extract may also suppress proteinase action in adjacent synovial tissue, thus affording additional protection to articular cartilage. It will require further studies to establish if A. galanga extract can reduce arthritis-associated inflammation in synovial membranes and MMPs production from this tissue.
The effects of A. galanga extract on key cartilage genes include some up-regulation of type II collagen, aggrecan and SOX9 expression, potentially indicating enhanced reparative activity, although there was some inhibition of aggrecan expression at high dose. To substantiate these effects more detailed studies are necessary in cartilage chondrocytes rather than SW1353 cells. It will also be necessary to evaluate signaling pathways and the environmental effects of fibroblast and chondrocytes, such as the release of proinflammatory cytokines in comparison with Diacerein r . To assess possible cytotoxicity of A. galanga, we determined LDH levels released from explants and cell cultures, which showed there was no evidence of increased cell death. These interesting in vitro effects of A. galanga extract indicate potential modes of action that might be similar to the commercially available drug, Diacerein r , suggesting that it is a good candidate for further in vivo evaluation as a chondroprotective agent and it may in the future find use as an adjunct to other anti-arthritic and anti-inflammatory treatments.
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